Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Collaboration to leverage Steritas’ STOX Suite in developing innovative treatments for autoimmune diseases.

Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 1.0% in the third quarter, ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Argenx Se (ARGX – Research Report). The company’s shares closed last Friday at $564.23. Don't Miss our Black Friday ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

November 11, 2024--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today ...

SE (NASDAQ:ARGX – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $595.04, but opened at $572.41. argenx shares last traded at ...

周二,Wolfe Research将argenx SE (NASDAQ: ARGX)的股票评级从Peerperform上调至Outperform,目标价为697.00美元。该公司预计,在肌炎和PFS项目的推动下,argenx到2025年将呈现积极发展态势,并有望在重症肌无力(MG)市场保持主导地位,尤其是在竞争对手Biohaven和Immunovant发布最新消息后。 Wolfe Research ...